Project Grant HT94252410318
Award Date 7/1/24
Completion Date 6/30/26
Dollars Obligated $457K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Clemson, SC 29634, USA
Similar Awards
- The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
- The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $525,000 Project Grant to Vanderbilt University Medical Center to investigate novel mechanisms of ovarian cancer initiation in the fallopian tube. The award, effective April 1, 2024 through March 31, 2026, supports biomedical research aimed at improving the health and care of military service members, veterans, and their families. As a sub-award under this grant, Vanderbilt University's...
- This Project Grant award of $750,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Houston System. The award is for the research project "CIRCULATING IMMUNE COMPLEXES AS BIOMARKERS FOR EARLY DETECTION AND MONITORING OF OVARIAN CANCER" with a performance period from May 1, 2025 to April 30, 2029. The project aims to develop innovative biomedical solutions that address critical health challenges...
- The U.S. Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), has awarded a $954,000 project grant to the Massachusetts Institute of Technology (MIT) for the research project "TUMOR-TARGETED NANOCARRIERS FOR EFFECTIVE IMMUNOMODULATION OF OVARIAN CANCER". The grant, with a performance period from May 1, 2025 to April 30, 2028, will support advanced biomedical research aimed at developing innovative medical solutions for military personnel...
- The Defense Health Agency awarded a $1,290,499.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "ENHANCING THE ANTITUMOR ACTIVITY OF NATURAL KILLER CELLS IN OVARIAN CANCER," is focused on conducting research to develop innovative approaches to understanding, detecting, and treating ovarian cancer. DFCI, a prestigious non-profit cancer research center, will...
- The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $467,742 Project Grant to the Regents of the University of Michigan to optimize a risk stratification model for ovarian cancer. The award will support research activities from September 1, 2024 through August 31, 2026. The University of Michigan, a top public research institution, has extensive experience conducting federal research and development projects for agencies such as the...
- The Department of the Army Medical Command awarded a $1,347,700 Project Grant to Sloan-Kettering Institute For Cancer Research under the Military Medical Research and Development program (CFDA 12.420). The grant will support development of an implantable nanosensor for early-stage ovarian cancer detection from June 2022 through June 2025. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions. This award...
- This Project Grant award, valued at $1,124,896.00 and funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The research aims to characterize the role of aberrant FGD1 splicing in brain and bone metastasis in clear cell renal cell carcinoma. The award period runs from July 15, 2025 through July 14, 2029. The Military Medical...
- The Defense Health Agency awarded Dana-Farber Cancer Institute a $1,046,135 project grant under the Military Medical Research and Development program to conduct research titled "Drugging the Undruggable: Programming Ovarian Cancer Cells as the Next-Generation Immunotherapy." The three-year award runs from May 15, 2023 to May 14, 2026. As the prime recipient, Dana-Farber will leverage its expertise in tumor biology, immunology and drug development to research new therapies for ovarian...
- The Department of the Army Medical Command awarded Brigham & Women's Hospital Inc. a $1,297,718 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund the identification of proteomic profiles and biological networks of early stage ovarian cancer from May 1, 2021 to April 30, 2025. Through this research, the grantee aims to transform healthcare for service members and the public by investigating medical solutions for the battlefield and...